drugset
drugset / Trial / NCT03587649

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649 ↗

Phase 1 Completed 12 enrolled Invicro
NaSingle-groupOpen-labelOther

Summary

The primary objective of this protocol is to examine \[18F\]MNI-1126 as a tool to assess synaptic density loss.

Timeline

Start
2018-05-07
Primary completion
2020-02-26
Completion
2020-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]MNI-1126 Unknown — —

Indications

Alzheimer disease Parkinson disease